VKTX - Viking Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
0
0
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
22,197
19,040
13,741
9,000
6,967
Selling General and Administrative
8,654
7,121
5,329
4,847
5,030
Total Operating Expenses
30,851
26,161
19,070
13,847
11,996
Operating Income or Loss
-30,851
-26,161
-19,070
-13,847
-11,996
Interest Expense
0
404
1,283
1,810
982
Total Other Income/Expenses Net
-8
1,386
345
1,064
-10,425
Income Before Tax
-23,569
-22,063
-20,578
-14,732
-23,404
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-23,569
-22,063
-20,578
-14,732
-23,404
Net Income
-23,569
-22,063
-20,578
-14,732
-23,404
Net Income available to common shareholders
-23,569
-22,063
-20,578
-14,732
-23,404
Reported EPS
Basic
-
-0.38
-0.79
-0.90
-3.68
Diluted
-
-0.38
-0.79
-0.90
-3.68
Weighted average shares outstanding
Basic
-
57,580
25,978
16,278
6,356
Diluted
-
57,580
25,978
16,278
6,356
EBITDA
-
-21,659
-19,295
-12,922
-22,422